Point72 DIFC Ltd Buys New Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Point72 DIFC Ltd purchased a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 66,615 shares of the company’s stock, valued at approximately $154,000. Point72 DIFC Ltd owned about 0.09% of Ventyx Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Opaleye Management Inc. purchased a new position in Ventyx Biosciences during the fourth quarter valued at approximately $2,816,000. Norden Group LLC purchased a new position in shares of Ventyx Biosciences during the 1st quarter valued at $59,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Ventyx Biosciences by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock worth $63,000 after acquiring an additional 4,553 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ventyx Biosciences during the first quarter worth $72,000. Finally, First Light Asset Management LLC purchased a new stake in shares of Ventyx Biosciences during the first quarter worth $3,437,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Analysts Set New Price Targets

VTYX has been the subject of a number of recent research reports. Wells Fargo & Company cut their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Oppenheimer lowered their target price on shares of Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, June 6th. Canaccord Genuity Group cut their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, September 23rd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.29.

Ventyx Biosciences Trading Down 4.6 %

VTYX stock opened at $2.08 on Wednesday. The business’s 50 day moving average is $2.21 and its 200-day moving average is $3.44. The firm has a market cap of $146.99 million, a P/E ratio of -0.64 and a beta of 0.37. Ventyx Biosciences, Inc. has a 1-year low of $1.79 and a 1-year high of $34.49.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.12. Sell-side analysts forecast that Ventyx Biosciences, Inc. will post -2.14 EPS for the current year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.